Health
Oxford University begins first human trial of Bundibugyo Ebola vaccine
Researchers are testing the ChAdOx BDBV vaccine on 50 volunteers to address the Bundibugyo ebolavirus strain currently spreading in the DRC.
Topic
Clinical Trials
Health
Weizmann Institute Alzheimer's immunotherapy clears Phase 1 safety trial
A Phase 1b trial of the immunotherapy IBC-Ab002 has successfully met safety endpoints, marking a potential shift in treating Alzheimer's as a systemic immune disorder.
Health
WHO launches clinical trial of antiviral to prevent Bundibugyo Ebola strain
Health officials have launched clinical trials to evaluate treatments and preventive drugs for the Bundibugyo strain of the Ebola virus. The studies target both active infections and post-exposure prophylaxis to combat the ongoing outbreak.
Business
Biogen tau-targeting Alzheimer’s drug slows cognitive decline in study
Researchers have unveiled mid-stage trial results for diranersen, an experimental drug that reduces abnormal tau production in Alzheimer’s patients.
Health
DR Congo reports 1,502 confirmed Ebola cases amid outbreak expansion
Confirmed Ebola cases in the Democratic Republic of the Congo have reached 1,502, creating a public health crisis across the nation's eastern provinces. Medical authorities face significant containment hurdles as the virus spreads through areas affected by conflict.
Health
DR Congo begins clinical trial for potential Ebola treatments
Health authorities have launched the PARTNERS clinical trial in the Democratic Republic of Congo to evaluate monoclonal antibodies and remdesivir. The study aims to determine the efficacy of these treatments against the rare Bundibugyo Ebola virus strain.
Health
Cancer Research Institute highlights patient success stories for immunotherapy
Immunotherapy is shifting the survival landscape for patients with advanced cancers by training the immune system to target malignant cells. While these treatments have led to significant clinical breakthroughs, experts emphasize that sustainable research funding remains vital.